The effect of the beta-emitting yttrium-90 citrate on the dose-response of dicentric chromosomes in human lymphocytes: a basis for biological dosimetry after radiosynoviorthesis.
The production of dicentric chromosomes in human lymphocytes by beta-particles of yttrium-90 (Y-90) was studied in vitro to provide a basis of biological dosimetry after radiosynoviorthesis (RSO) of persistent synovitis by intra-articular administration of yttrium-90 citrate colloid. Since the injected colloid may leak into the lymphatic drainage exposing other parts of the body to radiation, the measurement of biological damage induced by beta-particles of Y-90 is important for the assessment of radiation risk to the patients. A linear dose-response relationship (alpha = 0.0229 +/- 0.0028 dicentric chromosomes per cell per gray) was found over the dose range of 0.2176-2.176 Gy. The absorbed doses were calculated for exposure of blood samples to Y-90 activities from 40 to 400 kBq using both Monte Carlo simulation and an analytical model. The maximum low-dose RBE, the RBE(M) which is equivalent to the ratio of the alpha coefficients of the dose-response curves, is well in line with published results obtained earlier for irradiation of blood of the same donor with heavily filtered 220 kV X-rays (3.35 mm copper), but half of the RBE(M) relative to weakly filtered 220 kV X-rays. Therefore, it can be concluded that for estimating an absorbed dose during RSO by the technique of biological dosimetry, in vitro and in vivo data for the same radiation quality are necessary.
Schmid
E
E
Radiobiological Institute, University of Munich, Schillerstr. 42, 80336, Munich, Germany. ernst.schmid@lrz.uni-muenchen.de
Selbach
H-J
HJ
Voth
M
M
Pinkert
J
J
Gildehaus
F J
FJ
Klett
R
R
Haney
M
M
D001610:Beta Particles; D002869:Chromosome Aberrations / Q000528:radiation effects* / Q000706:statistics & numerical data; D002951:Citrates / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D066298:In Vitro Techniques; D007270:Injections, Intra-Articular; D008214:Lymphocytes / Q000528:radiation effects*; D008297:Male; D009010:Monte Carlo Method; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D012062:Relative Biological Effectiveness; D013585:Synovitis / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D014965:X-Rays
D002951:Citrates; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C045937:yttrium citrate